Back to Journals » Therapeutics and Clinical Risk Management » Volume 4 » Issue 5

Review of docetaxel in the treatment of gastric cancer

Authors Eric D Tetzlaff, Jonathan D Cheng, Jaffer A Ajani

Published 10 October 2008 Volume 2008:4(5) Pages 999—1007

DOI https://doi.org/10.2147/TCRM.S3226

Review by Single-blind

Peer reviewer comments 3

Eric D Tetzlaff1, Jonathan D Cheng1, Jaffer A Ajani2

1Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA; 2Gastrointestinal Medical Oncology, M.D. Anderson Cancer Center, Houston, TX, USA

Abstract: Gastric cancer is a global health problem accounting for 800,000 cancer related deaths annually. Often diagnosed at an advanced stage, the treatment of gastric cancer with chemotherapy is directed towards palliating cancer related symptoms with only modest improvements in survival. In addition, no regimen has emerged as a globally accepted standard. New therapeutic options are desperately needed for the treatment of gastric cancer. Docetaxel given in combination has recently emerged as a new option for patients with advanced gastric cancer. This review focuses on the treatment of advanced gastric cancer utilizing docetaxelbased therapy and the novel additions of biotherapy to the existing cytotoxic platforms. In addition, the current investigations of docetaxel for the treatment of potentially curable gastric cancer will be discussed.

Keywords: docetaxel, gastric cancer, chemotherapy, biotherapy

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Readers of this article also read:

Insulin resistance and inflammation markers in myocardial infarction

Gruzdeva O, Uchasova E, Dyleva Y, Belik E, Shurygina E, Barbarash O

Journal of Inflammation Research 2013, 6:83-90

Published Date: 17 June 2013

Anticancer efficacy of perillyl alcohol-bearing PLGA microparticles

Farazuddin M, Sharma B, Khan AA, Joshi B, Owais M

International Journal of Nanomedicine 2012, 7:35-47

Published Date: 5 January 2012

Treatment of severe psoriasis with infliximab

JA Leman, AD Burden

Therapeutics and Clinical Risk Management 2008, 4:1165-1175

Published Date: 5 December 2008

Pharmacological management of acute bronchiolitis

Melvin Wright, Charles J Mullett, Giovanni Piedimonte

Therapeutics and Clinical Risk Management 2008, 4:895-903

Published Date: 10 October 2008

The therapeutic effects of Rho-ROCK inhibitors on CNS disorders

Takekazu Kubo, Atsushi Yamaguchi, Nobuyoshi Iwata, Toshihide Yamashita

Therapeutics and Clinical Risk Management 2008, 4:605-615

Published Date: 6 June 2008

“One pill, once daily”: what clinicians need to know about Atripla™

Patrick G Clay, Tracey AH Taylor, Alan G Glaros, MaryPeace McRae, Charlott Williams, et al

Therapeutics and Clinical Risk Management 2008, 4:291-302

Published Date: 11 April 2008

Management of laryngopharyngeal reflux with proton pump inhibitors

Christina Reimer, Peter Bytzer

Therapeutics and Clinical Risk Management 2008, 4:225-233

Published Date: 8 February 2008

Clinical studies with oral lipid based formulations of poorly soluble compounds

Dimitrios G Fatouros, Ditte M Karpf, Flemming S Nielsen, Anette Mullertz

Therapeutics and Clinical Risk Management 2007, 3:591-604

Published Date: 15 September 2007